1. Suppression of non-muscle myosin II boosts T cell cytotoxicity against tumors.
- Author
-
Yang Y, Wen D, Lin F, Song X, Pang R, Sun W, Yu D, Zhang Z, Yu T, Kong J, Zhang L, Cao X, Liao W, Wang D, Yang Q, Liang J, Zhang N, Li K, Xiong C, and Liu Y
- Subjects
- Animals, Humans, Mice, Tumor Microenvironment immunology, Cell Line, Tumor, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism, Myosin Type II metabolism, Cytotoxicity, Immunologic, Transcription Factors metabolism, Transcription Factors genetics, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Actins metabolism, Neoplasms immunology, Neoplasms therapy, Neoplasms metabolism, Neoplasms pathology
- Abstract
Increasing evidence highlights the importance of immune mechanoregulation in establishing and sustaining tumor-specific cytotoxicity required for desirable immunotherapeutic outcomes. However, the molecular connections between mechanobiological inputs and outputs and the designated immune activities remain largely unclear. Here, we show that partial inhibition of non-muscle myosin II (NM II) augmented the traction force exerted by T cells and potentiated T cell cytotoxicity against tumors. By using T cells from mice and patients with cancer, we found that NM II is required for the activity of NKX3-2 in maintaining the expression of ADGRB3, which shapes the filamentous actin (F-actin) organization and ultimately attributes to the reduced traction force of T cells in the tumor microenvironment. In animal models, suppressing the NM II-NKX3-2-ADGRB3 pathway in T cells effectively suppressed tumor growth and improved the efficacy of the checkpoint-specific immunotherapy. Overall, this work provides insights into the biomechanical regulation of T cell cytotoxicity that can be exploited to optimize clinical immunotherapies.
- Published
- 2024
- Full Text
- View/download PDF